Obesity drug helpful for polycystic ovaries

	Tweet

The prescription weight-loss drug orlistat, sold as Xenical, appears to be as effective as the Diabetes drug metformin, sold as Glucophage, in the treatment of women with polycystic ovarian syndrome (PCOS), according to UK researchers.

Lead investigator Dr. Vijay Jayagopal told AMN Health that “orlistat can be used to treat women with PCOS and it is especially useful when obesity and PCOS co-exist.”

In polycystic ovary syndrome, a woman’s ovaries develop multiple cysts.

Symptoms can include excessive hairiness, obesity, menstrual abnormalities, and infertility. All of this may be caused by abnormally high production of male hormones in the ovaries.

PCOS is also believed to place women at increased risk for developing diabetes.

In their study, Jayagopal, of the University of Hull and colleagues randomized 21 women to receive metformin or orlistat three times a day. All had previously undergone an 8-week run-in period of dietary modification.

After 3 months, compared with baseline, both regimens produced a significant reduction in testosterone levels. Moreover, those in the orlistat group showed a greater weight reduction than those in the metformin group.

Writing in the Journal of Clinical Endocrinology and Metabolism, the authors say these findings reaffirm “the potential for orlistat to be a useful adjunct in the treatment of PCOS.” However, added Jayagopal, “the impact of such treatment on menstrual irregularities and subfertility requires evaluation in longer term studies.”

SOURCE: Journal of Clinical Endocrinology and Metabolism, February 2005. 

RELATED STORIES:
Statins may cut stroke disability, deaths   New anti-inflammatory drugs increase TB risk   Get your free prescriptions here   Merck board names committee on Vioxx withdrawal   UK lawmakers slam slack pharmaceutical regulation   E-prescribing Systems Can Boost Drug Cost Savings   Onyx Shares Fall on Cancer Drug Filing   Public to view drug side effects   Efficacy of blood pressure drug questioned   FDA: No increased cardiovascular risk with heartburn drugs   Scientist to submit Vioxx study, attorney says   Florida sues generic drug makers for overcharging

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]